Turn your clinical data into defensible dose decisions.
From inter-patient variability to exposure–response relationships, PhinC builds robust PopPK and PK/PD models to secure dose selection, optimize dosing regimens, and accelerate progression toward Phase II–III development.
Why PopPK & PK/PD are key to informed dose selection
The same dose never results in the same exposure—or the same response. Our models capture variability, explain its sources, and transform your data into actionable recommendations.
Quantify variability
Measure inter-individual and inter-occasion variability, and explain it through clinical covariates.
Simulate dosing scenarios
Quickly test dosing regimens and anticipate exposure and response in targeted populations.
Support the regulatory rationale
Justify dose selection (Phases II–III) using a traceable, defensible, model-based quantitative approach.
PopPK for Special Population Assessment
Population PK leverages all your clinical data to estimate PK parameters, quantify variability, and identify the factors driving it (body weight, sex, organ impairment, co-medications, food effects, etc.).
- ✓Identify key covariates and their clinical impact.
- ✓Predict exposure in special populations (pediatrics, renal/hepatic impairment, elderly subjects, obesity).
- ✓Reduce dedicated studies when modeling provides a robust quantitative alternative.
- ✓Cover a relevant dose range and secure Phase II/III decision-making.
PK/PD: Linking Concentration to Therapeutic Effect
PK/PD modeling describes how systemic exposure translates into response (efficacy or toxicity), accounting for patient variability, disease characteristics, and drug sensitivity.
- ✓Characterize mechanisms (effect delay, tolerance, biomarkers, disease progression).
- ✓Optimize dosing regimens through simulation.
- ✓Reduce uncertainty and better prepare confirmatory studies.
- ✓Converge toward the optimal dose using your Phase I/II data.
Proven expertise and recognized approaches
Controlled workflows, traceable analyses, and deliverables aligned with your internal and regulatory milestones.
Key deliverables
- ✓Model (structural + variability + covariates) and diagnostics.
- ✓Simulations to compare doses/regimens and populations.
- ✓Dose recommendations and quantitative rationale.
- ✓Regulatory-ready report with technical appendices.
Platforms & Ecosystem
PhinC excels in the use of modeling platforms such as MonolixSuite® and SAS®, and relies on recognized partners to promote best practices in pharmacometrics.